rijk

looks like, after a decade being down double digits, we finally might get our money back...... https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02835804-6A1219439&v=fc9bdb61fe50ea61f8225e24ce041a0e155a9400

if this is people corp, not sure why goevisit isn't mentioned, but the competition is.... People Connect Total Health Our proprietary, end-to-end virtual health solution that includes People Connect – online mental health support, medical consultation, , and medication delivery. Plan members have access to People Connect, access telemedicine services through either one of our health partners, Akira Health or Maple – all from the comfort of home. Complementing this service is the addition of PocketPills, Canada’s first true digital pharmacy that provides free delivery of acute and maintenance medications and helps plan sponsors realize savings through lower markup and dispensing fees. https://www.peoplecorporation.com/products-and-solutions/health-solutions/

it's a donut :( On March 2, 2021, United Therapeutics Corporation (the “Company”) decided to discontinue the development of Trevyent® (treprostinil), due to written comments provided by the U.S. Food and Drug Administration (the “FDA”) on February 25, 2021. The FDA provided these written comments following a meeting between the Company and the FDA to discuss the Company’s planned resubmission of its New Drug Application for Trevyent in light of a Complete Response Letter issued by the FDA in April 2020. The FDA’s comments indicated that the Company would need to both redesign the product to improve pump accuracy in certain respects and conduct a clinical study of the redesigned product. These additional steps would have caused considerable additional delay, and additional development efforts may not ultimately be successful in addressing the FDA’s comments. The Company decided that continued development of Trevyent was no longer commercially reasonable in light of this additional FDA feedback. Moreover, the FDA recently cleared another subcutaneous delivery system, the Remunity® Pump for Remodulin®. As noted in the Company’s Annual Report on Form 10-K, as of December 31, 2020, the Company’s consolidated balance sheet includes a $107.3 million in-process research and development (“IPR&D”) asset associated with the Company’s August 2018 acquisition of SteadyMed Ltd., the developer of Trevyent. The Company is conducting an impairment analysis for this IPR&D asset and expects to incur an impairment charge during the first quarter of 2021, potentially equal to some or all of the $107.3 million IPR&D asset. The Company plans to disclose the results of this impairment analysis, as well as any additional material financial statement impacts, in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.

not looking good... Trevyent. We submitted a 505(b)(1) NDA to the FDA for our Trevyent disposable treprostinil pump system in June 2019. In April 2020, the FDA issued a complete response letter (CRL) related to our NDA indicating that some of the deficiencies previously raised by the FDA had not yet been addressed to its satisfaction. We are evaluating the letter and will provide updates on our plans to resubmit our NDA at a later date. We have one year from the date of the CRL to resubmit our NDA to the FDA, which is expected to trigger a six-month review period by the agency.

..... 3 years later.... looks like the r&d pipeline is about to deliver its first (post spin-off) blockbuster drug...... “While we designed daridorexant to have the optimal profile for a sleep medicine, I am none-the-less stunned by the results. Once approved, by providing daridorexant to the millions of patients with insomnia, Idorsia will have a major impact on this medical, social, and economic problem. It has struck me particularly in these times of confinement that we are living through, that sleep problems are a major issue and require an extremely safe and effective drug that can be used by the many. With these results Idorsia is entering into a new era; less than 3 years since its creation, Idorsia is taking a huge step forward in delivering on the vision to become a fully-fledged biopharmaceutical company.” https://www.idorsia.com/media/news-details?newsId=2284972

seems like something is not right when you can make 74 million by under performing the s&p 500 by nearly 40% per year (5% vs 8.1%) for nearly two decades while there is a 6% hurdle rate with high watermark.........

making progress,... next hurdle is fda approval, expected on april 27, 2020, which would leave three years and four months (merger closed aug 30, 2018) to sign up 3000 patients.... https://www.prnewswire.com/news-releases/united-therapeutics-announces-fda-acceptance-of-trevyent-new-drug-application-for-review-300915684.html

israeli mergers usually take (a lot) longer, foreign holders need to complete an additional tax certificate to avoid local withholding tax, per ib the related paperwork will appear in the corporate actions tool..... hopefully in the near future.....

sounds like this could be a win win deal, eurobank finally makes some progress with restructuring and fairfax gets cheap assets? or are fairfax/pimco simply "stealing" ultra cheap assets? i hope that there has been a decent bidding process...... https://www.eurobank.gr/online/home/ViewNews2.aspx?id=2233&lang=en

fascinating to be invested in a biotech stock, you can almost feel the animal spirits...... this is far from a value stock, but the field they are in has endless potential and the team has demonstrated to be capable in building a 30 billion business from scratch in no time never done this, but i plan to stick with this one for the long run.....

hilarious and educational, nothing has changed in 70 years, beats 99% of all investment books, wonderful book!

thanks, indeed the difference is coming from the first 2 years

on his website, his fund outperforms the s&p over 17 years by a factor close to 2.5x morningstar is showing 15 year performance in line with s&p of just over 8%/year why the performances differ so much? http://www.fairholmefunds.com/overview http://performance.morningstar.com/fund/performance-return.action?t=FAIRX&region=usa&culture=en_US

what is also remarkable disgusting in this case is that citi is the (unsponsored) adr depository bank + financial advisor in the tender offer, how can they not know? they designed this transaction..... they are probably buying the shares of scared adr and untendered shareholders.......

In an agreement announced early Wednesday, Greece won additional pledges of debt relief, but nothing substantial until 2018 at the earliest, and only then if it continues to carry out painful reforms. Even so, the accord could help ease concerns about another flare-up of a crisis in Greece as the region deals with a mass influx of migrants and a continuing terrorist threat. Eurozone finance ministers also gave a green light for the next round of aid for Greece, money that would allow the country to pay bills in the coming months. Further final approvals for those disbursements will be needed, but ministers allocated 10.3 billion euros, or about $11.5 billion, for Greece, to be distributed in several stages starting with €7.5 billion as soon as the second half of June. http://www.nytimes.com/2016/05/25/business/international/greece-debt-relief-imf-eurozone-bailout.html